Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Richard D. Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8448-844X; OpenAlex author ID A5045482037. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 1, last author 7)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2011: 1 paper, 2 trials · 2012: 4 papers · 2013: 2 papers · 2014: 1 paper, 2 trials · 2015: 4 papers · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 17

  1. Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment. Co-author DOI 10.1200/po-25-00807↗
  2. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  3. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Last author DOI 10.1007/s10637-018-0676-8↗
  4. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Co-author DOI 10.1097/coc.0000000000000261↗
  5. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Co-author DOI 10.1097/rlu.0000000000001098↗
  6. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Last author DOI 10.1007/s00280-015-2814-8↗
  7. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Co-author DOI 10.1097/rlu.0000000000000837↗
  8. Management of borderline resectable pancreatic cancer. Last author DOI 10.4251/wjgo.v7.i10.241↗
  9. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. Co-author PMID 26254348↗
  10. Is there a role for second line therapy in advanced pancreatic cancer? Last author DOI 10.6092/1590-8577/2325↗
  11. First-line treatment for advanced pancreatic cancer. Last author DOI 10.6092/1590-8577/1477↗
  12. Biomarkers for pancreatic cancer: is it ready for primetime? Co-author DOI 10.6092/1590-8577/1676↗
  13. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Last author DOI 10.1177/1758834012453755↗
  14. What options are available for refractory pancreatic cancer? First author DOI 10.6092/1590-8577/720↗
  15. BRCA and pancreatic cancer: selection of chemotherapy. Co-author DOI 10.6092/1590-8577/727↗
  16. Systemic therapy of advanced pancreatic cancer: has the landscape changed? Last author PMID 22895284↗
  17. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Co-author DOI 10.1016/s1470-2045(10)70237-0↗

Trials 4

  1. Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer Principal investigator NCT02138383↗
  2. BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer Principal investigator NCT02155088↗
  3. SOM 230 and Gemcitabine in Advanced Pancreatic Cancer Principal investigator NCT01385956↗
  4. Phase I Trial of Combination of FOLFIRI and SOM 230 Principal investigator NCT01434069↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mokenge Peter Malafa · 5 shared papers, 2015–2026 · strength 0.58
  2. Sarah E. Hoffe · 4 shared papers, 2015–2026 · strength 0.57
  3. Pamela Joy Hodul · 3 shared papers, 2015–2026 · strength 0.45
  4. Amit Mahipal · 6 shared papers, 2013–2019 · strength 0.42
  5. Nicole Nardella · 2 shared papers, 2025–2026 · strength 0.40
  6. Muhammad Wasif Saif · 5 shared papers, 2012–2014 · strength 0.29
  7. Jessica M. Frakes · 2 shared papers, 2015–2025 · strength 0.27
  8. José M. Pimiento · 2 shared papers, 2016–2025 · strength 0.26
  9. Minsig Choi · 4 shared papers, 2012–2014 · strength 0.23
  10. Sophie Moravec · 1 shared paper, 2026 · strength 0.20
  11. Dae Won Kim · 1 shared paper, 2026 · strength 0.20
  12. Allan Andresson Lima Pereira · 1 shared paper, 2026 · strength 0.20
  13. Carmelo Blanquicett · 1 shared paper, 2026 · strength 0.20
  14. Jennifer B. Permuth · 1 shared paper, 2026 · strength 0.20
  15. Gregory M. Springett · 3 shared papers, 2015–2018 · strength 0.20
  16. James B. Yu · 1 shared paper, 2025 · strength 0.20
  17. Robin Park · 1 shared paper, 2025 · strength 0.20
  18. Jason W. Denbo · 1 shared paper, 2025 · strength 0.20
  19. Dae Won Kim · 1 shared paper, 2025 · strength 0.20
  20. Jason B. Fleming · 1 shared paper, 2025 · strength 0.20
  21. Nishi Kothari · 2 shared papers, 2013–2015 · strength 0.11
  22. Monique Z. Sajjad · 1 shared paper, 2018 · strength 0.10
  23. Domenico Coppola · 1 shared paper, 2019 · strength 0.10
  24. Heloisa Prado Soares · 1 shared paper, 2019 · strength 0.10
  25. Anuhya Kommalapati · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.